News

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the ...
Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma
Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in ...
First Patient Dosed In Phase 3 REVEAL Study Of ION582 For Angelman Syndrome
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. The initial ...
11 Most Undervalued US Stocks According To Analysts
He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...
PMLive14h
Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target
Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...
The Pharma Letter1d
Salanersen shines in early spinal muscular atrophy research
Biogen’s salanersen has shown promise in slowing neuronal damage and opening new motor milestones, according to interim ...
Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsight
The 7MM Polycythemia Vera market size reached approximately USD 2 billion in 2024 and is projected to grow significantly through 2034. Key players such as Incyte, PharmaEssentia, Protagonist ...
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results - The Globe and Mail
Detailed price information for Ionis Pharmaceuticals (IONS-Q) from The Globe and Mail including charting and trades.
Fierce Biotech2d
Biogen’s Spinraza follow-up helps children with SMA who didn’t benefit from Zolgensma
Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...
Biogen to Advance SMA Treatment Into Registrational Studies
Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.